Skip to main content
Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

HOME
ABOUT
AREAS OF FOCUS
INVESTOR RELATIONS
PRESS
- Close
- PRESS RELEASES
- STORIES
CONTACT US

Main Content

Slide

AKARI THERAPEUTICS IS AN INNOVATIVE TARGETED

ONCOLOGY COMPANY BUILT ON NEXT GENERATION

ANTIBODY-DRUG CONJUGATES (ADC)

CORPORATE PRESENTATION CORPORATE PRESENTATION

AND A NOVEL DISCOVERY ENGINE

RECENT PRESS RELEASES

Akari Therapeutics Presents Promising Immuno-OncologyData for its Novel Splicing-Targeted ADC Payload Driving ImmuneActivation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

November 10, 2025

Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

November 4, 2025

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

October 30, 2025

Akari Therapeutics Announces Launch of CEO Corner Platform

October 22, 2025

Akari Therapeutics Announces $2.5Million Registered Direct Offering

October 15, 2025

Footer

Follow Us

Privacy Statement

Copyright © 2025 · Akari Therapeutics · Site Designed by Polus Digital, Inc.